Actuate Therapeutics, Inc.
ACTU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001652935
No open-market purchases or sales by Actuate Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $20.6M in total; no superinvestor holds it.
Holders of 5% or more of ACTU
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Actuate Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BIOS Fund I, LP | 13D/A | 49.80%10.3M shares | −2.60 ppfrom 52.40% | May 27, 20252 filings | Jun 30, 2025 | SEC |
| Voss Capital, LLC | 13G | 5.30%1.23M shares | New | Dec 17, 20251 filing | Dec 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Actuate Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Dec 17, 202512:25 PM ET | Voss Capital, LLCand 4 others | 13G | 5.30%1.23M shares | New | Dec 15, 2025 | SEC |
| Jun 30, 202512:08 PM ET | BIOS Fund I, LPand 23 others | 13D/A | 49.80%10.3M shares | −2.60 ppfrom 52.40% | Jun 27, 2025 | SEC |
| May 27, 20254:15 PM ET | BIOS Fund I, LPand 23 others | 13D/A | 52.40%10.0M shares | – | May 22, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Actuate Therapeutics, Inc. shares.
No Form 144 notices for Actuate Therapeutics, Inc. are on file.